Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC

ESMO 2024

Lung, Respiratory and Thoracic Cancer

MARIPOSA: Amivantamab plus lazertinib reduced the incidence of acquired MET and EGFR resistance alterations versus osimertinib in patients with NSCLC

Lung, Respiratory and Thoracic Cancer

Prevalence of EGFR Mutations in Patients With Resected Stage I-III NSCLC: Results From the EARLY-EGFR Study

J Thorac Oncol

Soo RA, Reungwetwattana T, Perroud HA, Batra U, Kilickap S, Tejado Gallegos LF, Donner N, Elsayed M, Huggenberger R, Van Tu D

doi: 10.1016/j.jtho.2024.06.008

Lung, Respiratory and Thoracic Cancer

Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced/Metastatic NSCLC

J Thorac Oncol

Burotto M, Zvirbule Z, Alvarez R, Chewaskulyong B, Herraez-Baranda LA, Shearer-Kang E, Liu X, Tosti N, Williams P, Castro Sanchez AY, Zanghi J, Felip E

doi: 10.1016/j.jtho.2024.05.005

Leukemia

Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia

Leukemia

Wang J, Jiang B, Li J, Liu L, Du X, Jiang H, Hu J, Yuan M, Sakatani T, Kadokura T, Takeuchi M, Kosako M, Ma X, Girshova L, Tan J, Bondarenko S, Lee LWL, Khuhapinant A, Martynova E, Hasabou N

doi: 10.1038/s41375-024-02382-9

ESMO 2024

Lung, Respiratory and Thoracic Cancer

MARIPOSA-2: OS data continued to favor amivantamab plus chemotherapy over chemotherapy alone in patients with EGFR-mutated NSCLC

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Lu S, Zhang Y, Zhang G, Zhou J, Cang S, Cheng Y, Wu G, Cao P, Lv D, Jian H, Jin X, Chen C, Tian P, Wang K, Jiang G, Chen G, Chen Q, Zhao H, Ding C, Guo R, Sun G, Wang B, Jiang L, Liu Z, Fang J, Yang J, Zhuang W, Liu Y, Zhang J, Pan Y, Chen J, Yu Q, Zhao M, Cui J, Li D, Yi T, Yu Z, Yang Y, Zhang Y, Zhi X, Huang Y, Wu R, Chen L, Zang A, Cao L, Li Q, Li X, Song Y, Wang D, Zhang S, Ding L, Zhang L, Ji D, Shen Z

doi: 10.1016/j.lungcan.2024.107901

ELCC 2024

Lung, Respiratory and Thoracic Cancer

MARIPOSA-2: Improved post-progression outcomes with amivantamab plus chemotherapy in EGFR-mutated advanced NSCLC

Genitourinary Cancer

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Lancet

Choueiri TK, Albiges L, Barthélémy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ

doi: 10.1016/S0140-6736(24)01758-6

Related content

Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC

MARIPOSA: Amivantamab plus lazertinib reduced the incidence of acquired MET and EGFR resistance alterations versus osimertinib in patients with NSCLC

Prevalence of EGFR Mutations in Patients With Resected Stage I-III NSCLC: Results From the EARLY-EGFR Study

Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced/Metastatic NSCLC

Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia

MARIPOSA-2: OS data continued to favor amivantamab plus chemotherapy over chemotherapy alone in patients with EGFR-mutated NSCLC

Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial

MARIPOSA-2: Improved post-progression outcomes with amivantamab plus chemotherapy in EGFR-mutated advanced NSCLC

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study